Recursion Prices $200M Offering at $3.25, Adds Sanofi Milestone and Clinical Data
RXRX sits 34% above its 52-week low of $2.77.
Summary
Recursion priced a $200M stock offering at $3.25 per share — a discount to the $3.74 reference price — adding about 10% dilution while extending cash runway into 2029. The same filing disclosed positive REC-4881 and REC-1245 clinical data and a $10M Sanofi milestone.
Key Events · Financing and Capital Events · RXRX
-
Priced $200M Offering at $3.25
61,540,000 shares sold at $3.25 per share for gross proceeds of approximately $200M, below the $3.74 last reported sale on October 14, 2026. Closing expected October 16, 2026.
-
Roughly 10% Dilution to Holders
61.54M new shares against 533,191,318 shares outstanding as of June 30, 2026 — about a 10% increase in share count. Underwriting discount of $0.195/share implies ~$12.0M in gross fees.
-
Cash Runway Extended into 2029
Preliminary September 30, 2026 cash of ~$561M, including ~$86M net proceeds from 23,696,330 ATM shares sold in Q3 2026; combined with the offering, runway extends into 2029.
-
Sanofi Options First Development Candidate
Sanofi optioned the first candidate from the collaboration, triggering a $10M milestone (total $144M to date; >$300M remaining milestones). Phase 1 planned for 2027, funded by Sanofi.
Analysis · RXRX · Life Sciences
Recursion finalized a $200M underwritten offering of 61,540,000 shares at $3.25 — below the $3.74 last reported sale on October 14, 2026, so the deal was priced at a discount to the market. The raise adds roughly 10% to the share count (61.54M new shares against 533.2M outstanding as of June 30, 2026), but it is anchored by named healthcare investors (Janus Henderson, ARK, Invus, Driehaus, Longaeva) and extends the cash runway into 2029. Alongside the financing, the filing bundles two clinical readouts and a partnership milestone: updated REC-4881 FAP data (47% median polyp burden reduction, 92% upper GI response, durability off treatment) and initial REC-1245 data (3 partial responses, 91.7% disease control at doses >=45 mg), plus Sanofi optioning its first development candidate for a $10M milestone. The dilution is real, but the capital funds a registrational REC-4881 trial and REC-1245 expansion, and the clinical and partner updates give the raise a fundamental justification rather than a pure survival signal.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 40.4% of the 1069 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RXRX was trading at $3.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $2.77 to $7.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.